Sage Therapeutics Inc (SAGE)

Add to Watchlists
Create an Alert
180.26 -7.15  -3.82% NASDAQ Jul 16, 16:58 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/06/2019 08:00 EST Misc Sage Therapeutics Inc Third Quarter Earnings Conference Call in 2019
11/06/2019 Earnings Sage Therapeutics Inc Third Quarter Earnings in 2019 Release
08/06/2019 08:00 EDT Misc Sage Therapeutics Inc Second Quarter Earnings Conference Call in 2019
08/06/2019 Earnings Sage Therapeutics Inc Second Quarter Earnings in 2019 Release
06/05/2019 09:00 EDT Misc Sage Therapeutics Inc Annual General Meeting in 2018
05/02/2019 08:00 EDT Misc Sage Therapeutics Inc First Quarter Earnings Conference Call in 2019
05/02/2019 Earnings Sage Therapeutics Inc First Quarter Earnings in 2019 Release
02/19/2019 08:00 EST Misc Sage Therapeutics Inc Fourth Quarter Earnings Conference Call in 2018
02/19/2019 Earnings Sage Therapeutics Inc Fourth Quarter Earnings in 2018 Release
02/19/2019 Misc Sage Therapeutics Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.sagerx.com
  • Investor Relations URL: http://investor.sagerx.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Aug. 06, 2019
  • Last Earnings Release: May. 02, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.

Top Fund Holders

Symbol Name Weighting
BTEC Principal Healthcare Innovators ETF 2.54%
THISX T. Rowe Price Health Sciences I 2.43%
FBIOX Fidelity® Select Biotechnology 2.20%
XBI SPDR® S&P Biotech ETF 1.48%
IBB iShares Nasdaq Biotechnology ETF 1.33%
HFMRX Hartford MidCap R3 1.25%
LABU Direxion Daily S&P Biotech Bull 3X ETF 1.12%
FGCKX Fidelity® Growth Company K 0.98%
VISVX Vanguard Small Cap Value Index Inv 0.50%
VBR Vanguard Small-Cap Value ETF 0.48%
NAESX Vanguard Small Cap Index Inv 0.26%
VB Vanguard Small-Cap ETF 0.25%

Comparables

Edit

Excel Add-In Codes

  • Name: =YCI("SAGE","name")
  • Description: =YCI("SAGE","description")
  • Sector: =YCI("SAGE","sector")
  • Industry: =YCI("SAGE","industry")
  • Est. Current Fiscal Year End: =YCI("SAGE","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.